A longitudinal study of Florbetapir F 18 in patients participated in the Alzheimer'sDiseaseNeuroimaging Initiative (ADNI)

Trial Profile

A longitudinal study of Florbetapir F 18 in patients participated in the Alzheimer'sDiseaseNeuroimaging Initiative (ADNI)

Completed
Phase of Trial: Phase III

Latest Information Update: 08 Sep 2015

At a glance

  • Drugs Florbetapir F 18 (Primary)
  • Indications Alzheimer's disease
  • Focus Diagnostic use
  • Most Recent Events

    • 08 Sep 2015 New trial record
    • 17 Aug 2015 Results published in the JAMA Neurology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top